Compare Iron Mountain Inc (IRM) vs Summit Therapeutics Inc (SMMT) Price & Performance

Iron Mountain (IRM) trades at $124.55, up 2.46% on the day, with a bearish technical signal but strong recent earnings beats. Revenue growth is robust, reaching $6.90B in 2025, though net margins are thin at 5.54%. The stock shows high valuation multiples, including a P/E of 86.8, and carries significant debt, with total liabilities at $18.94B. Analyst consensus is bullish with a $141.50 price target, supported by institutional buying and positive Q2 2026 results highlighted by data center growth.

Outlook is cautiously optimistic due to earnings momentum and data center expansion, but high debt and declining paper storage pose risks. The stock offers potential upside to the consensus target, yet investors must weigh valuation concerns against operational strengths.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.